Vanguard Group Inc. Acquires 32,467 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Vanguard Group Inc. increased its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 0.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 16,909,720 shares of the company’s stock after purchasing an additional 32,467 shares during the period. Vanguard Group Inc. owned about 0.07% of Lyell Immunopharma worth $24,857,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC raised its position in Lyell Immunopharma by 251.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 10,687 shares of the company’s stock valued at $25,000 after buying an additional 7,650 shares during the last quarter. Advisor Group Holdings Inc. raised its position in Lyell Immunopharma by 3,125.3% in the 4th quarter. Advisor Group Holdings Inc. now owns 7,902 shares of the company’s stock valued at $27,000 after buying an additional 7,657 shares during the last quarter. Ethic Inc. acquired a new stake in Lyell Immunopharma in the 1st quarter valued at approximately $30,000. Mariner LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at approximately $35,000. Finally, Public Employees Retirement System of Ohio raised its position in Lyell Immunopharma by 109.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after buying an additional 14,229 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright dropped their target price on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock opened at $3.01 on Friday. The firm has a market cap of $764.84 million, a PE ratio of -3.24 and a beta of -0.56. Lyell Immunopharma, Inc. has a 52-week low of $1.32 and a 52-week high of $3.97. The business’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $1.98.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. As a group, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.91 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.